Aceso Life Science Group Limited provides earnings guidance for the year ended 31 March 2024. For the period, the company is expected to record a loss for the Reporting Period of approximately HKD 869 million, as compared to the loss of approximately HKD 208 million for the corresponding period in 2023. The increase in the Group's loss is mainly attributable to the (i) increase in fair value losses on financial assets at FVTPL (ii) increase in fair value losses on financial liabilities at FVTPL; (iii) increase in share of loss of associate company; (iv) increase in fair value losses on investment properties.